This California company does advanced (Phase 2/3) work on MERS and is using that basis for the COVID vaccine which they call INO 4800.
On a call yesterday, the CEO, Dr. Joseph Kim discussed the "Brothers in Arms" approach with others like Moderna, indicating they are working together against a common enemy.
There does seem to be some sibling rivalry as they took a couple shots at Moderna:
-Storing doses of INO's vaccine will be easier--it can be maintained at refrigerated temperatures. For Moderna, the mRNA vaccine needs to be stored at -80 degrees. No way delivering hundreds of millions or billions of doses will be easy at -80 degrees.
-There was some question of the data as it relates to T-Cells. So the comment about the vague results from Moderna on Monday was highlighted.
Interestingly, the CEO stated that this is not a zero sum game in that there will be one winner take all. Many different COVID vaccine creators and producers will be necessary. If this is true, that makes this much less risky for the Covid investor.
Inovio also has some advanced immunotherapies and vaccines for cancer treatment.
No comments:
Post a Comment